PEOPLE - Changes at Gambro Blood Component Technology:
This article was originally published in Clinica
Executive Summary
Gambro has announced that Ed Wood, president of Gambro Blood Component Technology (BCT), has left the company. Gambro said that it is "entering an exciting new phase of expansion and growth" which required "a new breed of global leadership". Gary Heath, head of the BCT management team, will serve as acting president until a replacement is found.
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.